Happy Thanksgiving! Save 50% on Your MarketBeat All Access Subscription.
  •  days
  •  Hours
  •  Minutes
  •  Seconds
×
S&P 500   4,026.12
DOW   34,347.03
QQQ   286.92
Considerations When Rolling Over a 401(k) into a Roth IRA
THE BEST BLACK FRIDAY DEAL YET (Ad)
Airbnb has a plan to fix cleaning fees
Saudi viewers angry over apparent ban on World Cup streaming
THE BEST BLACK FRIDAY DEAL YET (Ad)
Walmart shooting claims teen, young woman, father, mother
Cuba's informal market finds new space on growing internet
See how to make money instead of spending it on Black Friday with this offer (Ad)
Bird flu prompts slaughter of 1.8M chickens in Nebraska
US-England World Cup game seen by 19.98M on US television
S&P 500   4,026.12
DOW   34,347.03
QQQ   286.92
Considerations When Rolling Over a 401(k) into a Roth IRA
THE BEST BLACK FRIDAY DEAL YET (Ad)
Airbnb has a plan to fix cleaning fees
Saudi viewers angry over apparent ban on World Cup streaming
THE BEST BLACK FRIDAY DEAL YET (Ad)
Walmart shooting claims teen, young woman, father, mother
Cuba's informal market finds new space on growing internet
See how to make money instead of spending it on Black Friday with this offer (Ad)
Bird flu prompts slaughter of 1.8M chickens in Nebraska
US-England World Cup game seen by 19.98M on US television
S&P 500   4,026.12
DOW   34,347.03
QQQ   286.92
Considerations When Rolling Over a 401(k) into a Roth IRA
THE BEST BLACK FRIDAY DEAL YET (Ad)
Airbnb has a plan to fix cleaning fees
Saudi viewers angry over apparent ban on World Cup streaming
THE BEST BLACK FRIDAY DEAL YET (Ad)
Walmart shooting claims teen, young woman, father, mother
Cuba's informal market finds new space on growing internet
See how to make money instead of spending it on Black Friday with this offer (Ad)
Bird flu prompts slaughter of 1.8M chickens in Nebraska
US-England World Cup game seen by 19.98M on US television
S&P 500   4,026.12
DOW   34,347.03
QQQ   286.92
Considerations When Rolling Over a 401(k) into a Roth IRA
THE BEST BLACK FRIDAY DEAL YET (Ad)
Airbnb has a plan to fix cleaning fees
Saudi viewers angry over apparent ban on World Cup streaming
THE BEST BLACK FRIDAY DEAL YET (Ad)
Walmart shooting claims teen, young woman, father, mother
Cuba's informal market finds new space on growing internet
See how to make money instead of spending it on Black Friday with this offer (Ad)
Bird flu prompts slaughter of 1.8M chickens in Nebraska
US-England World Cup game seen by 19.98M on US television
NASDAQ:BBIO

BridgeBio Pharma - BBIO Stock Forecast, Price & News

$8.58
-0.21 (-2.39%)
(As of 11/25/2022 08:57 PM ET)
Add
Compare
Today's Range
$8.43
$8.85
50-Day Range
$8.47
$11.52
52-Week Range
$4.98
$18.13
Volume
316,100 shs
Average Volume
2.26 million shs
Market Capitalization
$1.28 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$23.00

BridgeBio Pharma MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
168.1% Upside
$23.00 Price Target
Short Interest
Bearish
21.08% of Float Sold Short
Dividend Strength
N/A
Sustainability
-2.31
Upright™ Environmental Score
News Sentiment
0.30mentions of BridgeBio Pharma in the last 14 days
Based on 6 Articles This Week
Insider Trading
Selling Shares
$510,589 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($3.89) to ($3.34) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.27 out of 5 stars

Medical Sector

372nd out of 1,044 stocks

Pharmaceutical Preparations Industry

176th out of 510 stocks

BBIO stock logo

About BridgeBio Pharma (NASDAQ:BBIO) Stock

BridgeBio Pharma, Inc. engages in the discovery, development, and delivery of various medicines for genetic diseases. The company has a pipeline of 30 development programs that include product candidates ranging from early discovery to late-stage development. Its products in development programs include AG10 and BBP-265, a small molecule stabilizer of transthyretin, or TTR that is in Phase 3 clinical trial for the treatment of TTR amyloidosis-cardiomyopathy, or ATTR-CM; BBP-831, a small molecule selective FGFR1-3 inhibitor, which is Phase 2 clinical trial to treat achondroplasia in pediatric patients; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD. The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 2 proof-of-concept clinical trial for Autosomal Dominant Hypocalcemia Type 1, or ADH1; and BBP-711 for the treatment of hyperoxaluria, as well as patients suffering from recurrent kidney stones. In addition, it engages in developing products for Mendelian, oncology, and gene therapy diseases. BridgeBio Pharma, Inc. has license and collaboration agreements with the Leland Stanford Junior University; and The Regents of the University of California; Leidos Biomedical Research, Inc. The company was founded in 2015 and is headquartered in Palo Alto, California.

Receive BBIO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for BridgeBio Pharma and its competitors with MarketBeat's FREE daily newsletter.

BBIO Stock News Headlines

BridgeBio Pharma (NASDAQ:BBIO) Trading Down 7.6% on Insider Selling
BridgeBio Pharma, Inc. (NASDAQ:BBIO) CEO Sells $325,616.00 in Stock
BridgeBio Pharma: Q3 Earnings Insights
BridgeBio Pharma: Down But Not Out
See More Headlines
Receive BBIO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for BridgeBio Pharma and its competitors with MarketBeat's FREE daily newsletter.

BBIO Company Calendar

Last Earnings
11/03/2022
Today
11/27/2022
Fiscal Year End
12/31/2022
Next Earnings (Estimated)
2/23/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:BBIO
Fax
N/A
Employees
576
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$23.00
High Stock Price Forecast
$30.00
Low Stock Price Forecast
$19.00
Forecasted Upside/Downside
+168.1%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
5 Analysts

Profitability

Net Income
$-562,540,000.00
Net Margins
-553.52%
Pretax Margin
-559.83%

Debt

Sales & Book Value

Annual Sales
$69.72 million
Book Value
($7.55) per share

Miscellaneous

Free Float
105,236,000
Market Cap
$1.28 billion
Optionable
Not Optionable
Beta
0.59

Key Executives

  • Dr. Neil Kumar Ph.D. (Age 43)
    Co-Founder, Pres, CEO & Director
    Comp: $757.86k
  • Dr. Charles J. Homcy M.D. (Age 74)
    Co-Founder, Chairman of Pharmaceuticals & Independent Lead Director
    Comp: $561.6k
  • Dr. Brian C. Stephenson C.F.A. (Age 41)
    Ph.D., CFO, Sec. & Principal Accounting Officer
    Comp: $836.6k
  • Dr. Richard H. Scheller Ph.D. (Age 69)
    Chairman of R&D and Director
    Comp: $552.4k
  • Dr. Frank McCormick Ph.D. (Age 72)
    Co-Founder & Chairman of Oncology
  • Dr. Uma Sinha Ph.D. (Age 65)
    Chief Scientific Officer
  • Grace Rauh
    VP of Communications
  • Mr. Eli M. Wallace Ph.D. (Age 55)
    Chief Scientific Officer of Oncology
  • Dr. Thomas Trimarchi Ph.D.
    Chief Product Officer
  • Dr. Eric Michael David J.D. (Age 50)
    M.D., Ph.D., Chief Exec. Officer of Gene Therapy













BBIO Stock - Frequently Asked Questions

Should I buy or sell BridgeBio Pharma stock right now?

5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for BridgeBio Pharma in the last year. There are currently 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" BBIO shares.
View BBIO analyst ratings
or view top-rated stocks.

What is BridgeBio Pharma's stock price forecast for 2023?

5 analysts have issued 12-month price targets for BridgeBio Pharma's shares. Their BBIO share price forecasts range from $19.00 to $30.00. On average, they predict the company's stock price to reach $23.00 in the next year. This suggests a possible upside of 168.1% from the stock's current price.
View analysts price targets for BBIO
or view top-rated stocks among Wall Street analysts.

How have BBIO shares performed in 2022?

BridgeBio Pharma's stock was trading at $16.68 on January 1st, 2022. Since then, BBIO stock has decreased by 48.6% and is now trading at $8.58.
View the best growth stocks for 2022 here
.

When is BridgeBio Pharma's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, February 23rd 2023.
View our BBIO earnings forecast
.

How were BridgeBio Pharma's earnings last quarter?

BridgeBio Pharma, Inc. (NASDAQ:BBIO) issued its earnings results on Thursday, November, 3rd. The company reported ($0.93) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.02) by $0.09. The business had revenue of $0.34 million for the quarter, compared to the consensus estimate of $6.26 million.

What other stocks do shareholders of BridgeBio Pharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other BridgeBio Pharma investors own include Advanced Micro Devices (AMD), Gilead Sciences (GILD), Cisco Systems (CSCO), Johnson & Johnson (JNJ), Pfizer (PFE), Roku (ROKU), Editas Medicine (EDIT), Block (SQ), Sorrento Therapeutics (SRNE) and Sarepta Therapeutics (SRPT).

When did BridgeBio Pharma IPO?

(BBIO) raised $225 million in an initial public offering on Thursday, June 27th 2019. The company issued 15,000,000 shares at a price of $14.00-$16.00 per share. J.P. Morgan, Goldman Sachs, Jefferies, SVB Leerink and KKR acted as the underwriters for the IPO and Piper Jaffray, Mizuho Securities, BMO Capital Markets and Raymond James were co-managers.

What is BridgeBio Pharma's stock symbol?

BridgeBio Pharma trades on the NASDAQ under the ticker symbol "BBIO."

Who are BridgeBio Pharma's major shareholders?

BridgeBio Pharma's stock is owned by many different retail and institutional investors. Top institutional investors include Vanguard Group Inc. (6.69%), Laurion Capital Management LP (1.35%), Renaissance Technologies LLC (0.91%), Jacobs Levy Equity Management Inc. (0.80%), Primecap Management Co. CA (0.69%) and Two Sigma Investments LP (0.58%). Insiders that own company stock include Brian C Stephenson, Cameron Turtle, Charles J Homcy, Douglas A Dachille, Frank Mccormick, Genetic Disorder LP Kkr, Michael Thomas Henderson, Neil Kumar, Randal W Scott, Richard H Scheller and Ronald J Daniels.
View institutional ownership trends
.

How do I buy shares of BridgeBio Pharma?

Shares of BBIO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is BridgeBio Pharma's stock price today?

One share of BBIO stock can currently be purchased for approximately $8.58.

How much money does BridgeBio Pharma make?

BridgeBio Pharma (NASDAQ:BBIO) has a market capitalization of $1.28 billion and generates $69.72 million in revenue each year. The company earns $-562,540,000.00 in net income (profit) each year or ($3.36) on an earnings per share basis.

How many employees does BridgeBio Pharma have?

The company employs 576 workers across the globe.

How can I contact BridgeBio Pharma?

BridgeBio Pharma's mailing address is 421 Kipling Street, Palo Alto CA, 94301. The official website for the company is bridgebio.com. The company can be reached via phone at (650) 391-9740.

This page (NASDAQ:BBIO) was last updated on 11/28/2022 by MarketBeat.com Staff